Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132198) titled 'Efficacy and Safety of Ivarmacitinib in the Treatment of Severe Alopecia Areata: A Real-World Clinical Study' on Sept. 10.

Study Type: Observational study

Study Design: Sequential

Primary Sponsor: Xi'an Jiaotong University Second Affiliated Hospital

Condition: alopecia areata

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-10-09

Target Sample Size: Ivarmacitinib Treatment Group:100;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=341789

Published by HT Digital Content Services with permission from Health Daily Digest....